Pluri Inc. (PLUR) AI Stock Analysis

Pluri Inc., based in Haifa, Israel, specializes in developing placenta-based cell therapy products to treat a spectrum of inflammatory, muscle injury, and hematologic conditions. Its primary technological focus is on PLX (placental expanded) cell therapies. The lead candidate, PLX-PAD, is in Phase III trials for muscle recovery following hip fracture surgery and Phase I/II trials for steroid-refractory graft versus host disease. In addition, PLX-PAD has completed trials for acute respiratory distress syndrome linked to COVID-19 and incomplete recovery post-bone marrow transplantation. The company is also advancing PLX-R18 for hematopoietic recovery and working with the National Institutes of Health and the U.S. Department of Defense on acute radiation syndrome treatments.

Pluri's annual revenue rose from $234,000 in FY2022 to $287,000 in FY2023, $326,000 in FY2024, and reached $1.3M in FY2025. In FY2026, revenue fell 24.0% to $1.0M. Gross margin shifted from -350.0% in FY2022 to 96.9% in FY2023 and 98.8% in FY2024, before settling at 49.0% in FY2025 and 44.6% in FY2026. Substantial operational expenditures, including research and development expense of $15.3M in FY2026, have resulted in deep operating deficits. Operating margin stood at -2454.5% in FY2026, yielding a net loss of -$23.8M and an EPS of -$1.19. In the latest quarter ended June 30, 2026, quarterly revenue declined 15.8% year-over-year.

As of June 30, 2026, Pluri held $7.8M in cash and short-term investments against $34.9M in total debt, resulting in net debt of $27.1M. The company operates with negative equity of -$23.0M and a current ratio of 0.27. Operating cash flow in FY2026 was -$19.6M, while capital expenditures were $633,000, leading to free cash flow of -$20.2M. Over the past five years, the company's share count expanded by 169.5% to help fund operations.

Pluri trades at a price-to-sales multiple of 11.5x, well above the 4.1x median of its US-listed Healthcare peers. Its enterprise value stands at $40.2M, with an enterprise value to revenue multiple of 39.6x. The forward price-to-earnings ratio is 3.6x compared to the peer median of 17.3x, and price-to-book is 306.6x. Pluri shares closed at $0.93 on October 16, 2026, having declined 78.6% over the trailing one-year period and 95.6% over five years, underperforming the S&P 500 benchmark returns of 16.8% and 83.0% over the same respective periods.

Wall Street coverage reflects a mean price target of $12.00, representing an upside of 1190.3% over the October 16, 2026 closing price of $0.93. The single analyst covering the stock models next fiscal year revenue of $10.2M, implying revenue growth of 294.0%, and an EPS estimate of -$1.90 compared to -$2.70 estimated for the current fiscal year. The company beat EPS estimates in 3 of the last 4 quarters. The next earnings date is scheduled for November 11, 2026.

This page is an AI-written research summary of Pluri Inc. (PLUR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PLUR income statement, PLUR balance sheet, PLUR key metrics, PLUR analyst forecast, PLUR chart. See the PLUR stock overview for the latest quote and news.